You are here: Home » News-IANS » Diaspora
Business Standard

Common prostate cancer treatment may lead to dementia later

IANS  |  New York 

Men with prostate who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as compared to prostate patients whose testosterone levels are not tampered with, say researchers including one of Indian-origin.

"The risk is real and, depending on the prior dementia history of the patient, we may want to consider alternative treatment," said senior author of the study Nigam Shah, Associate Professor at Stanford University School of Medicine.

Testosterone can promote the growth of prostate tumors, and so clinicians have used androgen deprivation therapy (ADT) to lower testosterone and other androgens in prostate patients since the 1940s.

The team looked at records from Stanford Medicine's clinical-research data warehouse for nearly 10,000 patients with prostate cancer.

Of the 1,829 who received androgen deprivation therapy, 7.9 percent developed dementia within five years, compared with 3.5 percent of those not treated with androgen deprivation therapy, said the study published in the journal JAMA Oncology.

The researchers, however, cautioned that prostate patients who are receiving ADT should not make changes to their medications without talking to their physicians.

The new retrospective study of patient records took only a few weeks, Shah said.

But retrospective studies of patient medical records are not meant to replace randomised clinical trials, he added.

--IANS

gb/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Common prostate cancer treatment may lead to dementia later

Men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as compared to prostate cancer patients whose testosterone levels are not tampered with, say researchers including one of Indian-origin.

Men with prostate who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as compared to prostate patients whose testosterone levels are not tampered with, say researchers including one of Indian-origin.

"The risk is real and, depending on the prior dementia history of the patient, we may want to consider alternative treatment," said senior author of the study Nigam Shah, Associate Professor at Stanford University School of Medicine.

Testosterone can promote the growth of prostate tumors, and so clinicians have used androgen deprivation therapy (ADT) to lower testosterone and other androgens in prostate patients since the 1940s.

The team looked at records from Stanford Medicine's clinical-research data warehouse for nearly 10,000 patients with prostate cancer.

Of the 1,829 who received androgen deprivation therapy, 7.9 percent developed dementia within five years, compared with 3.5 percent of those not treated with androgen deprivation therapy, said the study published in the journal JAMA Oncology.

The researchers, however, cautioned that prostate patients who are receiving ADT should not make changes to their medications without talking to their physicians.

The new retrospective study of patient records took only a few weeks, Shah said.

But retrospective studies of patient medical records are not meant to replace randomised clinical trials, he added.

--IANS

gb/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Common prostate cancer treatment may lead to dementia later

Men with prostate who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as compared to prostate patients whose testosterone levels are not tampered with, say researchers including one of Indian-origin.

"The risk is real and, depending on the prior dementia history of the patient, we may want to consider alternative treatment," said senior author of the study Nigam Shah, Associate Professor at Stanford University School of Medicine.

Testosterone can promote the growth of prostate tumors, and so clinicians have used androgen deprivation therapy (ADT) to lower testosterone and other androgens in prostate patients since the 1940s.

The team looked at records from Stanford Medicine's clinical-research data warehouse for nearly 10,000 patients with prostate cancer.

Of the 1,829 who received androgen deprivation therapy, 7.9 percent developed dementia within five years, compared with 3.5 percent of those not treated with androgen deprivation therapy, said the study published in the journal JAMA Oncology.

The researchers, however, cautioned that prostate patients who are receiving ADT should not make changes to their medications without talking to their physicians.

The new retrospective study of patient records took only a few weeks, Shah said.

But retrospective studies of patient medical records are not meant to replace randomised clinical trials, he added.

--IANS

gb/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard